Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.

Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther. 2009 Dec; 8(23):2263-72.

View in: PubMed

subject areas

Angiogenesis Inhibitors
Animals
Antibodies, Monoclonal
Apoptosis
Blotting, Western
Cell Proliferation
Disease Models, Animal
Drug Therapy, Combination
Female
Fluorescent Antibody Technique
Immunoenzyme Techniques
Immunoprecipitation
Integrin alphaVbeta3
Mice
Mice, Nude
Ovarian Neoplasms
Paclitaxel
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger
Tumor Cells, Cultured
Vascular Endothelial Growth Factor A

authors with profiles

Guillermo N Armaiz Pena

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support